ZEJULA® (niraparib) has been nominated for the Prix Galien USA Award for Best Pharmaceutical Product
TESARO, an oncology-focused business acquired by GlaxoSmithKline plc (LSE/NYSE: GSK), announces that ZEJULA® (niraparib) has been nominated for the Prix Galien USA Award for Best Pharmaceutical Product for the 2nd year running.
The Prix Galien was created in France in 1970 by a pharmacist named Roland Mehl. Its aim was to promote significant advances in pharmaceutical research. Since its creation, the Galien award has grown into a major event. It is seen as an influential event by all those interested in pharmaceutical research, including public authorities, scientists, pharmaceutical companies and medical press groups. For this reason, it is also considered as the industry’s equivalent of the Nobel prize and the highest accolade for pharmaceutical research and development.
The Prix Galien USA Awards Ceremony launched in 2007, awarding prizes for Best Pharmaceutical Agent (i.e. small molecule), Best Biotechnology Product, and Best Medical Technology approved by the FDA in the past five years. Up to three prizes may be awarded annually in each of these categories.